Skip to main content

Table 3 Side effects and adverse events by study group*a

From: Testing a home-based model of care using misoprostol for prevention and treatment of postpartum hemorrhage: results from a randomized placebo-controlled trial conducted in Badakhshan province, Afghanistan

 Misoprostol
(800mcg SL)
n = 40
Placebo
n = 39
RR 95% CIP value
Shivering33 (82.5)24 (61.5)1.34 (0.98, 1.74)0.05
Fever4 (10.0)7 (17.9)0.56 (0.14, 1.97)0.35
Vomiting6 (15.0)7 (17.9)0.84 (0.27, 2.58)0.72
Fainting2 (5.0)1 (2.6)1.95 (0.14, 54.1)1.0
Nausea6 (15.0)5 (12.8)1.17 (0.34, 4.19)0.78
Side effects reported as acceptable b31/35 (88.6)34/35 (97.1)0.91 (0.86, 1.06)0.36
Maternal death01  
Neonatal death01  
  1. Abbreviations: SL sublingual, RR relative risk, CI confidence interval
  2. * Data are presented as n (%)
  3. a Among those who received the study treatment, all received 600mcg oral misoprostol as prophylaxis with the exception of 4 women (1 in misoprostol arm; 3 in placebo arm)
  4. In nine cases participants did not report on acceptability of side effects (5 in misoprostol arm; 4 in placebo arm)